Generate Biomedicines financials
$14.16+2.24%
Close Nov 4, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $6.3M | $7.2M |
| Gross profit | $6.3M | $7.2M |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$71.6M | -$64.1M |
| Net income | -$67.3M | -$69.2M |
| Net margin | −1065.2% | −957.8% |
| Diluted EPS | $-0.52 | $-1.07 |
| EBITDA | -$68.4M | -$60.8M |
| Operating cash flow | -$57.9M | -$80.4M |
| Free cash flow | -$58.9M | -$84.2M |
| Diluted shares | 128.2M | 64.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $135.4M | $160.6M |
| Short-term investments | $322.1M | $356.1M |
| Total debt | $5.1M | $6.1M |
| Total assets | $561.7M | $625.7M |
| Total liabilities | $105.6M | $110.9M |
| Shareholders' equity | $456.0M | $514.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology